Crysvita Burosumab Application Scope

Crysvita (Burosumab) is indicated for the treatment of X-linked hypophosphatemia (XLH), a rare genetic disorder that leads to low phosphate levels in the blood and causes rickets or osteomalacia (softening of the bones). This condition impairs bone mineralization and can lead to growth problems, bone pain, and skeletal deformities.

Crysvita Burosumab Characteristics

Ingredients: Burosumab-twza
Properties: Burosumab is a fibroblast growth factor 23 (FGF23) blocking antibody that increases renal tubular reabsorption of phosphate and increases serum concentration of 1,25-dihydroxy vitamin D.
Packaging Specification: Common specifications include 10 mg/0.8 mL, 20 mg/1.0 mL, and 30 mg/1.0 mL in single-dose vials or prefilled syringes
Storage: Store refrigerated at 2°C to 8°C (36°F to 46°F) in the original carton to protect from light. Do not freeze or shake.
Expiry Date: The expiry date is lot-specific and printed on the packaging. Refer to the packaging for the exact date
Executive Standard: The product follows the standards set by the relevant
Approval Number: Refer to the regulatory approval number on the packaging
Date of Revision: The revision date is specific to the prescribing information or package insert and varies
Manufacturer: Refer to the manufacturer’s information on the packaging

Guidelines For The Use Of Crysvita Burosumab

Dosage and Administration:
- XLH in Adults: The recommended dose is 1 mg/kg body weight, rounded to the nearest 10 mg, administered every 4 weeks.
- XLH in Pediatric Patients: The recommended starting dose is 0.8 mg/kg of body weight, rounded to the nearest 10 mg, administered every two weeks.
- TIO in Adults and Pediatric Patients: Starting dose is 0.5 mg/kg every 4 weeks. Dose may be increased up to 2 mg/kg not to exceed 180 mg, administered every 2 weeks.
- Discontinue oral phosphate and active vitamin D analogs 1 week prior to initiation of treatment.
Adverse Reactions:
- Common adverse reactions in adults include back pain, headache, tooth infection, and restless legs syndrome.
- In pediatric patients, common adverse reactions include injection site reactions, headache, vomiting, and pyrexia.

Medication Limitations

Contraindications:
- Do not use in patients with severe renal impairment or end-stage renal disease.
- Do not initiate treatment if serum phosphorus is within or above the normal range for age.
Precautions:
- Monitor fasting serum phosphorus throughout treatment.
- Monitor for signs of hypersensitivity reactions.

Crysvita Burosumab Interactions

Drug Interactions: Concomitant use with oral phosphate and active vitamin Danalogs may increase the risk of hyperphosphatemia and ectopic mineralization; discontinue these agents prior to starting Crysvita.

Note:

If there is a new packaging for the drug, the new packaging shall prevail. The above information is sourced from HongKong DengYue Medicine. It is only for internal discussion among medical staff and does not serve as a basis for medication. For specific medication guidelines, please consult the attending physician.